Announcement • Jun 15
Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease Calithera Biosciences, Inc. announced the commercial launch of its next generation system: the Cala kIQ System, the first and only FDA-cleared wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor and Parkinson’s disease. The Cala kIQ System delivers Cala TAPS (Transcutaneous Afferent Patterned Stimulation) therapy, which is validated by large clinical studies and real-world evidence demonstrating clinically meaningful tremor reduction and improvement in activities of daily living (ADLs). The Cala kIQ System empowers patients and physicians by providing an on-demand, comfortable, at-home therapy for ease of use and management of action hand tremors. This type of tremor occurs when the patient undergoes intentional movement or posture. Millions of people across the US live with essential tremor or Parkinson’s disease, and diagnoses continue to rise. Treatment options for these conditions have historically been medications or, in more severe cases – surgery. The Cala kIQ System with TAPS therapy offers a non-invasive, non-pharmacologic solution with minimal side effects. The Cala kIQ System measures each patient's unique tremor physiology and individualizes a stimulation pattern for tremor relief. The system is designed to be easy to use for patients and easy to manage for clinicians. Therapy is on-demand for patients and delivered via a wrist-worn wearable. Designed with patients in mind for comfort and usability, the system also offers online data insights through the MyCala.com patient portal. Patients can see their therapy session results over time and choose to share with their providers to adjust treatment plans. Cala is committed to providing patients expanded access to Cala TAPS therapy. Cala is a contracted provider with major national and regional health plans for essential tremor including both commercial and Medical Advantage members. The Cala kIQ System is covered by the Veterans Affairs (VA) Health System at no cost to VA beneficiaries. Cala is working to secure additional coverage and reimbursement for the new breakthrough designated Parkinson's disease indication for the Cala kIQ System. Announcement • Feb 03
Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from NASDAQ Composite Index Calithera Biosciences, Inc. will be removed from the NASDAQ Composite Index. Announcement • Jan 26
Calithera Biosciences Board Approves Dissolution and Liquidation On January 9, 2023, Calithera Biosciences, Inc. announced that its Board of Directors had unanimously approved the dissolution and liquidation of Calithera Biosciences pursuant to a plan of complete liquidation and dissolution, subject to stockholder approval. The company also announced, that in order to reduce costs and in connection with the planned dissolution, the company was discontinuing all clinical development programs and reducingour workforce, including the termination of most employees by the end of the first quarter. In light of planned dissolution, on January 24, 2023, the company received written notice from The Nasdaq Stock Market LLC, or Nasdaq, advising the company that based upon Nasdaq's review and pursuant to Listing Rule 5101, Nasdaq believes that the company is a public shell," and that the continued listing of the company's securities is no longer warranted. The company will not appeal Nasdaq's determination. Therefore, the company expects, based on Nasdaq's written notice, that the trading of the company's common stock will be suspended as of the opening of business on February 2, 2023, and that Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission, which will remove the company's common stock from listing and registration on Nasdaq. 
